transdermal 17β-estradiol (t-E2; 50 μg/d) plus cyclic progesterone (Prometrium, 200 mg) 	oral conjugated equine estrogens (o-CEE; 0.45 mg/d) 	sleep disturbances	23507	23710	Among the three domains, only sleep disturbances showed a statistically significant difference between the two HT formulations (P = 0.029), with t-E2 improving more during follow-up than o-CEE (Table 2).
transdermal 17β-estradiol (t-E2; 50 μg/d) plus cyclic progesterone (Prometrium, 200 mg) or oral conjugated equine estrogens (o-CEE; 0.45 mg/d) 	placebo	average severity scores of hot flashes and night sweats	24152	24413	27 the average severity scores of hot flashes and night sweats were significantly reduced by both HT formulations when compared with PBO (P < 0.001 for both), with no difference between the o-CEE and t-E2 groups (P = 0.343 and P = 0.919, respectively; Table 2).
transdermal 17β-estradiol (t-E2; 50 μg/d) plus cyclic progesterone (Prometrium, 200 mg) 	oral conjugated equine estrogens (o-CEE; 0.45 mg/d) 	average severity scores of hot flashes and night sweats	24311	24413	with no difference between the o-CEE and t-E2 groups (P = 0.343 and P = 0.919, respectively; Table 2).
transdermal 17β-estradiol (t-E2; 50 μg/d) plus cyclic progesterone (Prometrium, 200 mg) 	oral conjugated equine estrogens (o-CEE; 0.45 mg/d) 	domain scores pertaining to sleep efficiency, sleep duration, or daytime dysfunction	23711	23918	There were no significant differences between groups for the changes in domain scores pertaining to sleep efficiency (P = 0.45), sleep duration (P = 0.38), or daytime dysfunction (P = 0.26) across follow-up.
transdermal 17β-estradiol (t-E2; 50 μg/d) plus cyclic progesterone (Prometrium, 200 mg) or oral conjugated equine estrogens (o-CEE; 0.45 mg/d) 	placebo	average severity scores of hot flashes and night sweats	24152	24412	27 the average severity scores of hot flashes and night sweats were significantly reduced by both HT formulations when compared with PBO (P < 0.001 for both), with no difference between the o-CEE and t-E2 groups (P = 0.343 and P = 0.919, respectively; Table 2)
transdermal 17β-estradiol (t-E2; 50 μg/d) plus cyclic progesterone (Prometrium, 200 mg) or oral conjugated equine estrogens (o-CEE; 0.45 mg/d) 	placebo	average severity scores of hot flashes and night sweats	24101	24151	As reported previously for the entire KEEPS cohort
